- Cell Biology
- Product Type
- Research Area
- New Products
- About Tocris
- Contact Us
Cholinesterases inactivate the neurotransmitter acetylcholine by catalyzing its hydrolysis to choline and acetic acid. Acetylcholinesterase (AChE) is found in erythroid cells and at neuronal synapses, whilst butyrylcholinesterase is mostly expressed in the liver.
|Cat No||Product Name / Activity|
|Acetylcholinesterase inhibitor. Also displays multiple other activities|
|Potent AChE inhibitor|
|Fluorescent, potent AChE and BChE inhibitor|
|Dual AChE and BChE inhibitor|
Cholinesterases inactivate the neurotransmitter acetylcholine by catalyzing its hydrolysis to choline and acetic acid. Acetylcholinesterase (AChE) is found in erythroid cells and at neuronal synapses, whilst butyrylcholinesterase is mostly expressed in the liver. The high enzymatic rate of AChE means that it effectively terminates signal transmission at cholinergic synpases.
AChE is the target of organophosphate nerve agents such as sarin and VX. Clinically, AChE inhibitors have found a number of uses, with physostigmine used to treat glaucoma. AChE inhibitors are also used in the management of mild to moderate Alzheimer's disease.
Tocris offers the following scientific literature for Cholinesterases to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.